Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): An exploratory prospective multicenter study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515433-15-02

Acronym

CHPAU2020/01

Enrollment

100

Registered

2025-01-29

Start date

2025-01-29

Completion date

Unknown

Last updated

2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome, atrial fibrillation

Brief summary

Occurrence during the 2 years of follow-up of a bleeding event defined by a score ≥2 according to the BARC scale

Detailed description

Occurrence of an event defined by the MACCE indicator, Occurrence of an ischemic event defined by the following composite indicator: death from cardiovascular causes, stroke or systemic embolism, non-fatal infarction and need for revascularization

Interventions

DRUGXarelto 10 mg film-coated tablets

DRUGCOUMADINE 5 mg

DRUGcomprimé sécable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Occurrence during the 2 years of follow-up of a bleeding event defined by a score ≥2 according to the BARC scale	—

Secondary

Measure	Time frame
Occurrence of an event defined by the MACCE indicator, Occurrence of an ischemic event defined by the following composite indicator: death from cardiovascular causes, stroke or systemic embolism, non-fatal infarction and need for revascularization	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026